VWR Corporation (VWR) Upgraded to Sell at BidaskClub
VWR Corporation (NASDAQ:VWR) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.
Other research analysts have also recently issued reports about the company. Zacks Investment Research cut VWR Corporation from a “buy” rating to a “hold” rating in a research report on Monday, June 5th. William Blair cut VWR Corporation from an “outperform” rating to a “market perform” rating in a research report on Monday, May 15th. Finally, TheStreet raised VWR Corporation from a “c” rating to a “b-” rating in a research report on Wednesday, April 19th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $30.50.
Shares of VWR Corporation (NASDAQ VWR) traded down 0.03% during midday trading on Friday, reaching $32.99. The company had a trading volume of 188,488 shares. The company has a 50 day moving average of $33.00 and a 200 day moving average of $30.13. The firm has a market capitalization of $4.35 billion, a price-to-earnings ratio of 30.55 and a beta of 1.19. VWR Corporation has a 12-month low of $24.42 and a 12-month high of $37.25.
VWR Corporation (NASDAQ:VWR) last announced its earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.04. The business had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.16 billion. VWR Corporation had a return on equity of 15.54% and a net margin of 3.12%. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period last year, the firm posted $0.42 earnings per share. Analysts anticipate that VWR Corporation will post $1.86 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in VWR Corporation by 4,641.8% in the first quarter. BlackRock Inc. now owns 4,072,333 shares of the medical research company’s stock worth $114,840,000 after buying an additional 3,986,452 shares during the last quarter. Shapiro Capital Management LLC bought a new position in VWR Corporation during the first quarter worth $66,793,000. JPMorgan Chase & Co. boosted its position in VWR Corporation by 79.2% in the first quarter. JPMorgan Chase & Co. now owns 4,531,105 shares of the medical research company’s stock worth $127,777,000 after buying an additional 2,002,306 shares during the last quarter. Harris Associates L P boosted its position in VWR Corporation by 43.3% in the first quarter. Harris Associates L P now owns 5,250,960 shares of the medical research company’s stock worth $148,077,000 after buying an additional 1,587,214 shares during the last quarter. Finally, Earnest Partners LLC boosted its position in VWR Corporation by 116.8% in the first quarter. Earnest Partners LLC now owns 1,797,102 shares of the medical research company’s stock worth $50,678,000 after buying an additional 968,313 shares during the last quarter.
About VWR Corporation
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.